期刊文献+

膦甲酸钠氯化钠注射液联合泛昔洛韦片治疗头面部带状疱疹的临床观察 被引量:13

Clinical observation of foscarnet sodium and sodium chloride injection combined with famciclovir in the treatment of head herpes zoster
下载PDF
导出
摘要 观察静滴膦甲酸钠氯化钠注射液联合口服泛昔洛韦片对治疗头面部带状疱疹的临床疗效及安全性。本文将98例头面部带状疱疹患者分为对照组48例与治疗组50例,观察口服泛昔洛韦片(对照组)和口服泛昔洛韦片联合静滴膦甲酸钠氯化钠注射液(治疗组)治疗头面部带状疱疹的临床疗效及安全性。根据复诊或随访比较两组患者的疗效评价参数,分析得出治疗组总有效率(96.0%)明显优于对照组(79.2%,P<0.05);治疗组在止痛、结痂、脱痂时间方面显著优于对照组(P<0.05)。在治疗头面部带状疱疹中,应用膦甲酸钠氯化钠注射液联合泛昔洛韦片,可较快使得疼痛缓解、皮损减少,安全性高且疗效佳,值得临床推广。 In this study,98 cases of head-to-face herpes zoster patients were divided into the control group(48 cases)and the treatment group(50 cases) to observe the clinical efficacy and safety of oral famciclovir tablets and oral famciclovir tablets combined with intravenous sodium infusion of intravenous drip Phosphate sodium for the treatment of head-to-face herpes zoster.According to the follow-up comparison of the efficacy evaluation parameters of the two groups,the total effective rate of the treatment group was 96.0%,which was significantly better than that of the control group(79.2%)(P〈0.05);The group had significantly better pain relief,scarring,and dislocation time than the control group. The difference was statistically significant(P〈0.05),and there was no significant difference in the time to stop snoring(P〈0.05). In the treatment of head-to-face herpes zoster,the use of sodium folinate sodium chloride injection combined with famciclovir tablets,can make the pain relief,skin lesions reduce faster,with high safety and good efficacy,which is worth clinical promotion.
作者 胡孟娇 武松江 曾文波 刘志军 HU Mengjiao,WU Songjiang,ZENG Wenbo, LIU Zhijun(Department of Dermatology, the First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, Chin)
出处 《中南医学科学杂志》 CAS 2018年第2期139-141,共3页 Medical Science Journal of Central South China
关键词 膦甲酸钠 泛昔洛韦 带状疱疹 toscamet sodium tamciclovir herpes zoster
  • 相关文献

参考文献3

二级参考文献17

  • 1金伟华,王晓蕙,陈华.阿昔洛韦静脉滴注导致急性肾衰[J].药物不良反应杂志,2006,8(5):385-386. 被引量:3
  • 2周村建,王莉,郭在培,涂亚庭,卢念祖,郝飞.不同剂量和疗程伐昔洛韦治疗带状疱疹的多中心随机双盲对照研究[J].临床皮肤科杂志,2007,36(7):420-422. 被引量:19
  • 3Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activi- ty, pharmacokinetic properties and therapeutic use in immunocompro- mised patients with viral infections [ J ]. Drugs, 1994,48 (2) :199 -226.
  • 4Karoline B, Jindrich C, Jonas SC. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet [ J ]. Med Microbiol Immuuo1,2011,200 ( 3 ) : 193 - 202.
  • 5Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing fos- carnet with vidarabine for acyclovir-resistant mucocutaneous herpes sim- plex in the acquired immunodeficiency syndrome[J]. The AIDS Clinical Trials Group. N Engl J Med,1991,325(8) : 551 -555.
  • 6Gerard L, Salmon-Ceron D. Pharmacology and clinical use of foscarnet [ J ]. International Journal of Antimicrobial Agents, 1995,5 (4) : 209 - 217.
  • 7Jacobson MA. Review of the toxicities of foscarnet [ J]. AIDS, 1992,5 (suppl 1) :S11 -17.
  • 8Choudhury D,Z Ahmed. Drug-associated renal dysfunction and injury[J].Nephrology,2006,(02):80-91.
  • 9Gunness P,Aleksa K,Bend J. Acyclovir-induced nephrotoxicity:the role of the acyclovir aldehyde metabolite[J].TRANSLATIONAL RESEARCH,2011,(05):290-301.
  • 10Izzedine H,Launay-Vacher V,Deray G. Antiviral drug-induced nephrotoxicity[J].American Journal of Kidney Diseases,2005,(05):804-817.

共引文献51

同被引文献97

引证文献13

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部